Anticoagulation in COVID-19 : what do we know today and what remains to be defined? . A critical review of the Asoneumocyte Vascular Committee.

Anticoagulación en COVID-19, ¿qué sabemos hoy y qué falta definirse? : una revisión crítica del Comité Vascular Asoneumocito.

Published 2021-03-08

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 32 No. 1 (2020)
Section
Topics review
How to Cite
Anticoagulation in COVID-19 : what do we know today and what remains to be defined? . A critical review of the Asoneumocyte Vascular Committee.
rev. colomb. neumol. [Internet]. 2021 Mar. 8 [cited 2024 Nov. 23];32(1):98-114. Disponible en: https://doi.org/10.30789/rcneumologia.v32.n1.2020.517
DOI

https://doi.org/10.30789/rcneumologia.v32.n1.2020.517
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Oscar Sáenz Morales
Asociación Colombiana de Neumología y Cirugía de Tórax
    Mauricio Orozco Levi
    Asociación Colombiana de Neumología y Cirugía de Tórax
      Ingrid Martínez
      Asociación Colombiana de Neumología y Cirugía de Tórax
        Nelson Gamba
        Asociación Colombiana de Neumología y Cirugía de Tórax
          Ana Rubio
          Asociación Colombiana de Neumología y Cirugía de Tórax
            Show authors biography

            Oscar Sáenz Morales,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Mauricio Orozco Levi,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Ingrid Martínez,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Nelson Gamba,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Ana Rubio,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Julián Cortez,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            José Blanco,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Alejandro Londoño,

            Médico Internista Neumólogo; miembro del Comité de Enfermedad Vascular Pulmonar de la Asociación Colombiana de Neumología.

            Desde diciembre del 2019 emergió la infección por coronavirus en el mundo, la cual se declaró pandemia por la Organización Mundial de la Salud (OMS) el 11 de marzo de 2020. Se estableció como epicentro la ciudad de Wuhan, capital de la provincia de Hubei, China (1). Rápidamente se identificó el agente causal de esta enfermedad, un betacoronavirus conocido como síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) (2). Al corte del 05 de junio de 2020, el Centro Europeo para la Prevención y Control de Enfermedades reportaba 6 475 644 casos, con 386 544 decesos en el mundo (3). Para esta misma fecha, en nuestro país se reportaban 35 120 casos y 1087 muertes (4).

            Article visits 511 | PDF visits 1629

            Downloads

            Download data is not yet available.
            1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20. doi: 10.1056/NEJMoa2002032.
            2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. doi: 10.1016/S0140-6736(20)30251-8.
            3. European Centre for Disease Prevention and control [Internet]. 2020. COVID-19 pandemic. Disponible en: https://www.ecdc.europa.eu/en/covid-19-pandemic
            4. Revista Semana [Internet]. Coronavirus en Colombia hoy 4 de junio: cifra de recuperados sube a 12.921. 2020. Disponible en: https://www.semana.com/casos-coronavirus-colombia-hoy1087-muertos-35120-contagiados-4-de-junio/676304/
            5. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-4. Doi: 10.1111/jth.14830.
            6. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002. Doi: 10.1111/jth.14888.
            7. Minet C, Potton L, Bonadona A, Hamidfar-Roy R, Somohano CA, Lugosi M, et al. Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis. Crit Care. 2015;19(1):1-9. doi: 10.1186/s13054-015-1003-9.
            8. Yan Z, Wei C, Meng X, Yuanjie L, Yang Y, Jing Z, et al. Análisis clínico de 7 casos de nueva neumonía grave por coronavirus complicada con isquemia de extremidades. Chinese J Hematol. 2020;(41). Doi: 10.3760/cma.j.issn.0253-2727.2020.0006(5).
            9. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N Engl J Med. 2020;382(20):e60. Doi: 10.1056/NEJMc2009787.
            10. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90. Doi: 10.1001/jamaneurol.2020.1127.
            11. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20:1135-40. doi: 10.1016/S1473-3099(20)30434-5.
            12. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517-9. doi: 10.1111/jth.14844.
            13. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844- 7. doi: 10.1111/jth.14768.
            14. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438-40. doi: 10.1016/S2352-3026(20)30145-9.
            15. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786-7. doi: 10.1111/jth.14781.
            16. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845-54. doi: 10.1182/blood-2017-10-804096.
            17. Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost. 2020;46(1):89-95. doi: 10.1055/s-0039-1694995.
            18. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol. 2009;145(1):24-33. doi: https://doi.org/10.1111/j.1365-2141.2009.07600.x.
            19. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: A meta-analysis of randomized controlled trials. J Thromb Haemost. 2016;14(3):518-30. doi:10.1111/jth.13230.
            20. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-30.
            21. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-94. doi: 10.1111/jth.14578.
            22. Iba T, Di Nisio M, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):1-7. doi: 10.1136/bmjopen-2017-017046.
            23. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. doi: 10.1126/science.abb2507.
            24. Belen-Apak FB, Sarialioglu F. The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARSCoV2 by inhibition of host cell proteases? Med Hypotheses. 2020;142:109743. doi: 10.1016/j.mehy.2020.109743.
            25. Hoffmann M, Kleine-Weber H, Krueger N, Mueller MA, Drosten C, Poehlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020;2020.01.31.929042. doi: https://doi.org/10.1101/2020.01.31.929042.
            26. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. doi:10.1002/path.1570.
            27. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-8. doi: 10.1001/jamacardio.2020.1017.
            28. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653-9. doi: 10.1056/NEJMsr2005760.
            29. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431-40. doi: 10.1056/NEJMoa2006923.
            30. Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020;18(5):1020-2. doi: 10.1111/jth.14821.
            31. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
            32. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi: 10.1016/S0140- 6736(20)30937-5.
            33. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-4. doi: 10.1038/s41418-020-0530-3.
            34. McGonagle D, O’Donnell J, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy (PIC) in COVID-19 pneumonia. Lancet Rheumatol. 2020;2019(20):1-9. doi: 10.1016/S2665-9913(20)30121-1.
            35. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77-83. doi: 10.1016/j.thromres.2019.07.013.
            36. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3.
            37. Adam SS, Key NS, Greenberg CS. D-dimer antigen: Current concepts and future prospects. Blood. 2009;113(13):2878-87. doi: 10.1182/blood-2008-06-165845.
            38. Harper PL, Theakston E, Ahmed J, Ockelford P. D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J. 2007;37(9):607- 13. doi: 10.1111/j.1445-5994.2007.01388.x.
            39. Stein PD, Hull RD, Patel KC, Olson RE, Ghali WA, Brant R, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism. Ann Intern Med. 2004;140(8):589- 607. doi: 10.7326/0003-4819-140-8-200404200-00005.
            40. Trapani LM. Thromboelastography: Current applications, future directions. Open J Anesthesiol. 2013;03(01):23-7. doi: http://dx.doi.org/10.4236/ojanes.2013.31007.
            41. Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev. 2012;26(1):1-13. doi: 10.1016/j.tmrv.2011.07.005.
            42. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-42. doi: 10.1111/jth.14850.
            43. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6. doi: https://doi.org/10.1111/jth.14810.
            44. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800. doi: 10.1056/NEJM199909093411103.
            45. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9. doi: 10.1111/jth.14817.
            46. Bompard F, Monnier H, Saab I, Tordjman M, Abdoul H, Fournier L, et al. Pulmonary embolism in patients with Covid-19 pneumonia. Eur Respir J. 2020;57(1). doi: 10.1183/13993003.01365-2020.
            47. Kreuziger LB, Lee A, Garcia D, Cuker A, Cushman M, DeSancho M, et al. COVID-19 and VTE/anticoagulation: frequently asked questions. 2020. Disponible en: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation
            48. Song JC, Wang G, Zhang W, Zhang Y, Li WQ, Zhou Z, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020;7(1):19. doi: 10.1186/s40779-020-00247-7.
            49. Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;(0123456789):3-5. doi: 10.1007/s11739-020-02331-1.
            50. Sociedad Española de Trombosis y Hemostasia [Internet]. Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes. 2020. Disponible en: https://www.covid-19.seth.es/recomendaciones-de-tromboprofilaxis-y-tratamientoantitrombotico-en-pacientes-con-covid-19/
            51. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963-8. doi: 10.1001/archinte.164.9.963.
            52. Hull RD, Merali T, Mills A, Stevenson AL, Liang J. Venous thromboembolism in elderly high- risk medical patients: Time course of events and influence of risk factors. Clin Appl Thromb. 2013;19(4):357-62. doi: 10.1177/1076029613481105.
            53. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167(14):1471-5. doi: 10.1001/archinte.167.14.1471.
            54. Dalen JE, Stein PD, Plitt JL, Jaswal N, Alpert JS. Extended thromboprophylaxis for medical patients. Am J Med. 2020;133(1):9-11. doi: 10.1016/j.amjmed.2019.05.050.
            55. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-23. doi: 10.1056/NEJMoa1111096.
            56. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379(12):1118-27. doi: 10.1056/NEJMoa1805090.
            57. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950-73. doi: 10.1016/j.jacc.2020.04.031.
            58. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020:1-10. doi: 10.1007/s00134-020-06062-x.
            59. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52. doi: 10.1016/j.chest.2015.11.026.

            Information

            Journal history

            Keywords

            QR code

            Funding

            Support + Info: Here

             

             

            Directories and indexes

            Google Scholar profile

            Most read in the last 30 days

            Current Issue

            Sistema OJS 3.4.0.7 - Metabiblioteca |